Facing Cardiovascular Diseases (CVD)

Clinical tests

Cardiovascular diseases are the number one cause of death worldwide. More than 40% of middle-aged adults are affected, mostly without knowing it. Inflammation is one of the main causes – and at the same time an opportunity to recognise health risks in time and take preventive action.

Most common cause of death

Over 17 Million deaths from CVD each year

Cardiovascular disease remains the No. 1 silent killer and accounts for 31% of all deaths globally
More than 40% of middle-aged adults have cardiovascular disease without their own knowledge
With 3.9 million deaths in Europe, it costs the EU economy € 210 billion every year
Saving lives requires early detection before cardiovascular symptoms develop

The importance of inflammation linked to CVD

Inflammation has been idenfied as a major contributor to the development and progression of cardiovascular disease
Inflammation serves as excellent risk marker for CVDs
Currently, inflammation is measured through blood tests, which are invasive and are often performed too late

Narrowing the diagnostic gap

Screening saves lifes

More than 80% of patients experiencing heart attacks have never been examined for underlying cardiovascular disease (Circulation 2020: Cardiovascular Quality and Outcomes)
Failing to diagnose cardiovascular disease leads to high death rates from heart attacks
Atherosclerosis is common in almost half of middle-aged adults who have no prior history of heart attack or cardiac disease (SCAPIS study in 30,000 women and men), so millions of adults don’t realize they have coronary artery disease until a health crisis makes them aware of their illness
Early detection before symptoms develop is a potential life saver

Pro-inflammatory biomarker

Pro-inflammatory screening helps identify unknown cardiovascular risks, so you can take steps to prevent further damage to your heart.

Several pro-inflammatory biomarkers have been linked to an increased risk of atherosclerosis and cardiovascular death, including C-reactive protein, interleukin-6, tumor necrosis factor-alpha, neutrophils, and others
Our saliva test platform DefenceDX targets a rapidly growing demand for non-invasive health tests along with the need for early detection of cardiovascular diseases
DefenceDX is developed as a more accessible and more convenient diagnostic tool compared to traditional blood tests
Click to access the login or register cheese